Completed PHASE3 INTERVENTIONAL NCT00594737

Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia

An Open Label Pilot Study of the Effects of Memantine Administration on FDG-PET in Frontotemporal Dementia

Sponsor: H. Lundbeck A/S

Updated 5 times since 2017 Last updated: Jun 1, 2012 Started: Oct 31, 2007 Primary completion: Jun 30, 2012 Completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00594737, this PHASE3 trial focuses on Frontotemporal Dementia and remains completed. Sponsored by H. Lundbeck A/S, it has been updated 5 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

H. Lundbeck A/S
Tiffany Chow, MD

Data source: Rotman Research Institute at Baycrest

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada